Tenax Therapeutics Reports Third-Quarter 2026 Results and Corporate Update
Tenax Therapeutics said completed statistical analyses of LEVEL yielded a predictive enrichment strategy being applied in Am.
Story updates
12:06:45 PM UTC
SquawkNews
Tenax Therapeutics reported a third-quarter 2026 net loss of $16.7 million, compared with $15.8 million a year earlier, and cash and cash equivalents of $113.7 million at September 30. The company said its cash runway is expected to fund operations through fiscal 2028, subject to changes following…